Annual report pursuant to Section 13 and 15(d)

Goodwill and In-process R&D (Details)

v3.21.1
Goodwill and In-process R&D (Details) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2017
Goodwill and In-Process R&D      
Balance of finite-lived intangible assets $ 5,866,000 $ 5,866,000  
Goodwill and intangible asset impairment 0    
Goodwill 1,452,338 1,452,338  
Goodwill gross   2,200,000  
Goodwill fair value   1,500,000  
Goodwill impairment loss 0 737,000  
In-process R&D      
Goodwill and In-Process R&D      
Change in finite-lived intangible assets $ 0 $ 0  
Pelican Therapeutics, Inc.      
Goodwill and In-Process R&D      
Goodwill acquired     $ 2,200,000
Pelican Therapeutics, Inc. | In-process R&D      
Goodwill and In-Process R&D      
Finite-lived intangible assets acquired     $ 5,866,000